Foghorn Therapeutics: Q4 Earnings Insights
Foghorn Therapeutics (NASDAQ:FHTX) reported its Q4 earnings results on Thursday, March 7, 2024 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Foghorn Therapeutics beat estimated earnings by 25.0%, reporting an EPS of $-0.57 versus an estimate of $-0.76.
Revenue was up $1.58 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.41 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Foghorn Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.75 | -0.73 | -0.72 | -0.62 |
| EPS Actual | -0.34 | -0.70 | -0.73 | -0.69 |
| Revenue Estimate | 4.52M | 6.26M | 5.04M | 8.48M |
| Revenue Actual | 17.48M | 5.60M | 5.31M | 4.18M |
** Listen to the earnings announcement yourself by clicking here. **
To track all earnings releases for Foghorn Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.